Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: June 2009
-
By Suresh Pillai — Beckman Asks for Dismissal in Patent Dispute with Sequenom Following the completion of a Markman hearing in a dispute with Sequenom Inc. concerning patents covering genotyping methods, Beckman Coulter has asked the District Court to dismiss its complaint. In the lawsuit, Beckman Coulter had contended that Sequenom willfully infringed Beckman's…
-
By Christopher P. Singer — FierceBiotech published its annual "Fierce 15" list of what it considers to be among the most promising of the up-and-coming companies in the biotechnology industry. FierceBiotech, a daily biotech industry news and article provider, has been publishing the Fierce 15 since 2003. The companies below (listed alphabetically) were named…
-
By Donald Zuhn — IPO Continues to Support 14-Year Exclusivity Period The Intellectual Property Owners Association (IPO), reporting on last week's announcement that the White House believes a 7-year data exclusivity period "strikes the appropriate balance between innovation and competition," reminded its members today that the IPO Board adopted a resolution in September 2008…
-
By Christopher P. Singer — In June 29, 2009 press release, the U.S. Patent and Trademark Office announced that it has agreed with the National Board of Patents and Registration of Finland (NBPR) to establish a Patent Prosecution Highway (PPH) program. As mentioned in prior posts regarding other participant Offices, the motivation behind the…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Dey, L.P. et al. v. Teva Parenteral Medicines, Inc. et al.1:09-cv-00087; filed June 23, 2009 in the Northern District of West Virginia…
-
June 29-30 – Product and Pipeline Enhancement for Generics (Marcus Evans) – Washington, DC July 6, 2009 – Prior Art & Obviousness 2009: The PTO & CAFC Perspective on Patent Law Sections 102 & 103 (Practising Law Institute) – New York, NY July 8, 2009 – Markman Hearings and Claim Construction in Patent Litigation (Practising…
-
By Donald Zuhn — Reuters reports that the White House sent a letter to Rep. Henry Waxman (D-CA), the Chairman of the House Energy and Commerce Committee, on Thursday stating that a follow-on biologics regulatory pathway providing a 7-year data exclusivity period would "strike[] the appropriate balance between innovation and competition." According to the…
-
By Kevin E. Noonan — A great deal has been written over the past week about Venezuela's new patented drug policy. Last Saturday, President Hugo Chavez (at right) announced that his government would "shake up" Venezuela's intellectual property laws, particularly with respect to patents on medicines. As reported by Reuters and the Associated Press,…
-
By Donald Zuhn — Last month, the Federal Circuit affirmed the judgment of the District Court for the Central District of California granting Defendant-Appellee Oxford Gene Technology's motion to dismiss for lack of personal jurisdiction. Oxford filed the motion to dismiss after Plaintiff-Appellant Autogenomics filed suit against Oxford seeking a declaratory judgment of invalidity,…
-
By Suresh Pillai — Caraco Motion for Summary Judgment in Prandin® Case Denied The U.S. District Court for the Eastern District of Michigan has denied a motion for summary judgment brought by Caraco Pharmaceutical Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. (the majority shareholder of Caraco) in their patent suit with Novo Nordisk over…
Patent Docs 